Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU program CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU program